Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 5,130,272
  • Shares Outstanding, K 165,760
  • Annual Sales, $ 2,171 M
  • Annual Income, $ 186,000 K
  • 36-Month Beta 0.33
  • Price/Sales 2.35
  • Price/Cash Flow 14.16
  • Price/Book 2.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.22 +2.52%
on 08/10/17
42.97 -27.90%
on 07/19/17
-10.69 (-25.65%)
since 07/17/17
3-Month
30.22 +2.52%
on 08/10/17
42.97 -27.90%
on 07/19/17
-10.84 (-25.92%)
since 05/17/17
52-Week
30.22 +2.52%
on 08/10/17
50.10 -38.16%
on 11/01/16
-14.56 (-31.97%)
since 08/17/16

Most Recent Stories

More News
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Dr. Reddy's Laboratories Limited

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) concerning...

RDY : 30.99 (+0.13%)
Dr. Reddy's (RDY) Alert: J&W Investigates Dr. Reddy's Laboratories Ltd.; Has Your Dr. Reddy's Investment Declined in Value?

Shareholder rights law firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and certain of its officers. Dr. Reddy's...

RDY : 30.99 (+0.13%)
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) concerning possible violations...

RDY : 30.99 (+0.13%)
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Dr. Reddy's Laboratories Limited

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's"...

RDY : 30.99 (+0.13%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Dr. Reddy's Laboratories Ltd. (RDY)

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors...

RDY : 30.99 (+0.13%)
Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

ENZ : 11.08 (+0.18%)
RDY : 30.99 (+0.13%)
EXEL : 26.84 (+0.22%)
SNY : 48.65 (+0.45%)
Dr. Reddy's and CHD Bioscience Announce Global License and Commercialization Agreement for Phase III Clinical Trial Candidate for Mitigation of Surgical Site Infections

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and CHD Bioscience Inc., a privately-held biopharmaceutical company, today announced a global licensing agreement for...

RDY : 30.99 (+0.13%)
Dr. Reddy's Q1 FY18 Financial Results

--EBITDA at Rs. 3.4 billion (10.1% of Revenues)

RDY : 30.99 (+0.13%)
Dr. Reddy's to Release Q1 FY18 Results on July 27, 2017

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the First Quarter ended June 30, 2017 on Thursday, July 27, 2017 after the Board Meeting. The results...

RDY : 30.99 (+0.13%)
VIVUS Settles with Teva on Weight Management Drug Generic

VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight...

AGEN : 3.61 (-1.10%)
VVUS : 1.02 (unch)
RDY : 30.99 (+0.13%)
TEVA : 17.67 (+1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Support & Resistance

2nd Resistance Point 31.20
1st Resistance Point 31.07
Last Price 30.98
1st Support Level 30.79
2nd Support Level 30.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.